Ovarian Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Ovarian Cancer, including details on symptoms, causes, treatment, information.

Volume 4 (2007), Issue 9 (September)

1. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers.
   Clin Cancer Res, 13(17): 5144-9. [Abstract] [Full-text]
2. BRCA1a has antitumor activity in TN breast, ovarian and prostate cancers.
   Oncogene, 26(41): 6031-7. [Abstract] [Full-text]
3. Low-molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma.
   Cancer, 110(6): 1264-71. [Abstract] [Full-text]
4. Metastatic patterns at autopsy in patients with ovarian carcinoma.
   Cancer, 110(6): 1272-80. [Abstract] [Full-text]
5. Novel germline mutations in BRCA2 gene among 96 hereditary breast and breast-ovarian cancer families from Kerala, South India.
   J Cancer Res Clin Oncol, 133(11): 867-74. [Abstract] [Full-text]
6. Bias versus causality: interpreting recent evidence of association between endometriosis and ovarian cancer.
   Fertil Steril, 88(3): 588-93. [Abstract] [Full-text]
7. Novel biocompatible intraperitoneal drug delivery system increases tolerability and therapeutic efficacy of paclitaxel in a human ovarian cancer xenograft model.
   Cancer Chemother Pharmacol, 60(6): 907-14. [Abstract] [Full-text]
8. Screening for BRCA1 and BRCA2 mutations in Eastern Finnish breast/ovarian cancer families.
   Clin Genet, 72(4): 311-20. [Abstract] [Full-text]
9. Therapeutic efficacy of astatine-211-labeled trastuzumab on radioresistant SKOV-3 tumors in nude mice.
   Int J Radiat Oncol Biol Phys, 69(2): 572-9. [Abstract] [Full-text]
10. Squamous cell carcinoma arising in a dermoid cyst of the ovary: a case series.
    BJOG, 114(10): 1283-7. [Abstract] [Full-text]
11. Centralisation of services for the management of ovarian cancer: arguments for.
    BJOG, 114(10): 1188-90. [Abstract] [Full-text]
12. Centralisation of services for the management of ovarian cancer: arguments against.
    BJOG, 114(10): 1183-5; discussion 1186-7. [Abstract] [Full-text]
13. Inclusion of CA-125 does not improve mathematical models developed to distinguish between benign and malignant adnexal tumors.
    J Clin Oncol, 25(27): 4194-200. [Abstract] [Full-text]
14. Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT.
    J Clin Oncol, 25(27): 4187-93. [Abstract] [Full-text]
15. Small cell carcinoma of pulmonary type inside a microinvasive mucinous cystadenocarcinoma of the ovary: a case report.
    Int J Gynecol Pathol, 26(4): 426-31. [Abstract] [Full-text]
16. The clinical importance of Ki-67, p16, p14, and p57 expression in patients with advanced ovarian carcinoma.
    Int J Gynecol Pathol, 26(4): 418-25. [Abstract] [Full-text]
17. Expression and prognostic significance of cyclin D3 in ovarian adenocarcinomas.
    Int J Gynecol Pathol, 26(4): 410-7. [Abstract] [Full-text]
18. Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis.
    Int J Gynecol Pathol, 26(4): 404-9. [Abstract] [Full-text]
19. Prognostic value of measurements of angiogenesis in serous carcinoma of the ovary.
    Int J Gynecol Pathol, 26(4): 395-403. [Abstract] [Full-text]
20. Molecular genetic evidence of an independent origin of serous low malignant potential implants and lymph node inclusions.
    Int J Gynecol Pathol, 26(4): 387-94. [Abstract] [Full-text]
21. Estrogen receptor alpha and progesterone receptor expression in ovarian adult granulosa cell tumors and Sertoli-Leydig cell tumors.
    Int J Gynecol Pathol, 26(4): 375-82. [Abstract] [Full-text]
22. Molecular genetic evidence supporting the neoplastic nature of the Leydig cell component of ovarian Sertoli-Leydig cell tumors.
    Int J Gynecol Pathol, 26(4): 368-74. [Abstract] [Full-text]
23. CD10 expression in pure stromal and sex cord-stromal tumors of the ovary: an immunohistochemical analysis of 101 cases.
    Int J Gynecol Pathol, 26(4): 359-67. [Abstract] [Full-text]
24. Drug safety evaluation through biomarker analysis--a toxicity study in the cynomolgus monkey using an antibody-cytotoxic conjugate against ovarian cancer.
    Toxicol Appl Pharmacol, 224(1): 12-8. [Abstract] [Full-text]
25. EF24 induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by increasing PTEN expression.
    J Biol Chem, 282(39): 28609-18. [Abstract] [Full-text]
26. Molecular description of a 3D in vitro model for the study of epithelial ovarian cancer (EOC).
    Mol Carcinog, 46(10): 872-85. [Abstract] [Full-text]
27. Ovarian metastases of appendiceal tumors with goblet cell carcinoidlike and signet ring cell patterns: a report of 30 cases.
    Am J Surg Pathol, 31(10): 1502-11. [Abstract] [Full-text]
28. Primary endometrioid adenocarcinoma of the vagina: a clinicopathologic study of 18 cases.
    Am J Surg Pathol, 31(10): 1490-501. [Abstract] [Full-text]
29. Targeted optical fluorescence imaging of human ovarian adenocarcinoma using a galactosyl serum albumin-conjugated fluorophore.
    Cancer Sci, 98(11): 1727-33. [Abstract] [Full-text]
30. Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome.
    Nat Clin Pract Oncol, 4(10): 578-90. [Abstract] [Full-text]
31. Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk.
    Am J Epidemiol, 166(8): 894-901. [Abstract] [Full-text]

© 2004-2008 Ovarian Cancer Research Today. All Rights Reserved.